Capital Advisors Inc. OK Boosts Stake in Edwards Lifesciences Corp (NYSE:EW)

Capital Advisors Inc. OK increased its position in Edwards Lifesciences Corp (NYSE:EW) by 200.0% in the 2nd quarter, Holdings Channel reports. The firm owned 4,854 shares of the medical research company’s stock after buying an additional 3,236 shares during the period. Capital Advisors Inc. OK’s holdings in Edwards Lifesciences were worth $376,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. National Asset Management Inc. raised its stake in shares of Edwards Lifesciences by 27.5% during the 1st quarter. National Asset Management Inc. now owns 2,753 shares of the medical research company’s stock worth $520,000 after buying an additional 594 shares in the last quarter. Smithfield Trust Co. raised its stake in shares of Edwards Lifesciences by 410.1% during the 2nd quarter. Smithfield Trust Co. now owns 1,413 shares of the medical research company’s stock worth $98,000 after buying an additional 1,136 shares in the last quarter. Tocqueville Asset Management L.P. raised its stake in shares of Edwards Lifesciences by 195.5% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 111,390 shares of the medical research company’s stock worth $7,698,000 after buying an additional 73,690 shares in the last quarter. Kentucky Retirement Systems purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $2,384,000. Finally, Cozad Asset Management Inc. raised its stake in shares of Edwards Lifesciences by 180.2% during the 2nd quarter. Cozad Asset Management Inc. now owns 38,206 shares of the medical research company’s stock worth $2,640,000 after buying an additional 24,569 shares in the last quarter. 79.70% of the stock is owned by institutional investors and hedge funds.

Shares of EW stock traded up $0.57 during mid-day trading on Wednesday, hitting $83.87. 1,992,354 shares of the company’s stock were exchanged, compared to its average volume of 3,835,366. Edwards Lifesciences Corp has a fifty-two week low of $51.51 and a fifty-two week high of $87.79. The stock has a 50-day simple moving average of $80.37 and a two-hundred day simple moving average of $81.92. The company has a quick ratio of 2.24, a current ratio of 3.08 and a debt-to-equity ratio of 0.15. The stock has a market cap of $51.79 billion, a price-to-earnings ratio of 72.52, a PEG ratio of 2.79 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.19. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 17.21%. The business had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $782.90 million. As a group, analysts anticipate that Edwards Lifesciences Corp will post 1.86 earnings per share for the current fiscal year.

In related news, VP Donald E. Bobo, Jr. sold 13,074 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $67.46, for a total value of $881,972.04. Following the transaction, the vice president now directly owns 85,906 shares of the company’s stock, valued at approximately $5,795,218.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Huimin Wang sold 591 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $70.00, for a total value of $41,370.00. Following the completion of the transaction, the vice president now directly owns 93,792 shares in the company, valued at $6,565,440. The disclosure for this sale can be found here. Insiders sold a total of 352,504 shares of company stock worth $26,493,197 over the last ninety days. Corporate insiders own 1.48% of the company’s stock.

EW has been the topic of a number of research reports. Canaccord Genuity upped their price target on Edwards Lifesciences from $86.00 to $89.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Wolfe Research initiated coverage on Edwards Lifesciences in a report on Friday, September 11th. They issued an “underperform” rating on the stock. Raymond James upped their price target on Edwards Lifesciences from $83.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. SVB Leerink upped their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, Credit Suisse Group upped their price target on Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $84.42.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: Strangles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.